What's Happening?
Generare, a Paris-based techbio company, has raised €20 million in a Series A funding round to expand its efforts in decoding microbial chemistry. The company uses high-throughput cloning and sequencing technology to screen microbial genomes, aiming to identify
and characterize bioactive molecules for drug development. Generare claims to have characterized more novel small molecules in 2025 than the rest of the field combined. The funding will support a ten-fold scale-up of their molecule library, with plans to increase from 200 to over 2,000 compounds by 2027.
Why It's Important?
This development represents a significant advancement in drug discovery, as Generare's approach could unlock a vast array of previously inaccessible bioactive molecules. By expanding the library of characterized molecules, the company could provide new opportunities for pharmaceutical and agrochemical industries to develop innovative products. The success of Generare's platform could lead to breakthroughs in treating various diseases, potentially transforming the landscape of drug development and offering new solutions for unmet medical needs.
What's Next?
Generare plans to scale up its operations, doubling its team and expanding its molecule library. The company aims to collaborate with major pharmaceutical and agrochemical companies to further explore the potential of these newly characterized molecules. As the platform continues to evolve, it may attract additional investment and partnerships, accelerating the pace of discovery and application of novel compounds in various industries.
